4.57
price down icon12.45%   -0.65
after-market Dopo l'orario di chiusura: 4.57
loading
Precedente Chiudi:
$5.22
Aprire:
$5.02
Volume 24 ore:
1.90M
Relative Volume:
1.43
Capitalizzazione di mercato:
$513.24M
Reddito:
$20.65M
Utile/perdita netta:
$-192.65M
Rapporto P/E:
-1.7645
EPS:
-2.59
Flusso di cassa netto:
$-134.39M
1 W Prestazione:
-20.93%
1M Prestazione:
-27.80%
6M Prestazione:
-5.58%
1 anno Prestazione:
-65.59%
Intervallo 1D:
Value
$4.54
$5.02
Intervallo di 1 settimana:
Value
$4.54
$5.92
Portata 52W:
Value
$4.305
$13.24

Verve Therapeutics Inc Stock (VERV) Company Profile

Name
Nome
Verve Therapeutics Inc
Name
Telefono
(978) 501-3026
Name
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
VERV's Discussions on Twitter

Confronta VERV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VERV
Verve Therapeutics Inc
4.57 513.24M 20.65M -192.65M -134.39M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-04-08 Iniziato H.C. Wainwright Buy
2023-04-13 Iniziato Canaccord Genuity Buy
2023-02-01 Iniziato Cantor Fitzgerald Neutral
2022-12-15 Iniziato Goldman Sell
2022-10-06 Iniziato Credit Suisse Neutral
2022-08-25 Aggiornamento Stifel Hold → Buy
2022-06-17 Iniziato BMO Capital Markets Outperform
2022-02-18 Iniziato RBC Capital Mkts Outperform
2021-09-24 Iniziato Stifel Hold
2021-07-12 Iniziato Guggenheim Buy
2021-07-12 Iniziato JP Morgan Neutral
2021-07-12 Iniziato Jefferies Buy
2021-07-12 Iniziato William Blair Outperform
Mostra tutto

Verve Therapeutics Inc Borsa (VERV) Ultime notizie

pulisher
Mar 30, 2025

Swiss National Bank Purchases 18,000 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Did Verve Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– VERV - ACCESS Newswire

Mar 29, 2025
pulisher
Mar 26, 2025

Investigation announced for Long-Term Investors in shares - openPR.com

Mar 26, 2025
pulisher
Mar 26, 2025

Pixalate Releases Q4 2024 United Kingdom Connected TV (CTV) Ad Supply Chain Trends Report: Samsung Smart TV Leads in Device Market Share (30%); Ad Fraud (IVT) Rate Hits 16% - GlobeNewswire Inc.

Mar 26, 2025
pulisher
Mar 25, 2025

Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts - Seeking Alpha

Mar 25, 2025
pulisher
Mar 24, 2025

Verve Therapeutics Announces Clearance of Investigational - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Verve Therapeutics Says US FDA Clears Verve-102 IND Application for Premature Coronary Artery Disease - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

Game-Changing FDA Green Light: Verve's One-Time Gene Therapy Takes On High Cholesterol - Stock Titan

Mar 24, 2025
pulisher
Mar 22, 2025

Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

Mar 22, 2025
pulisher
Mar 21, 2025

VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 21, 2025
pulisher
Mar 17, 2025

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by Arizona State Retirement System - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by US Bancorp DE - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

Verve Therapeutics Inc (VERV): Significant Improvements, Worth Considering - Stocks Register

Mar 14, 2025
pulisher
Mar 08, 2025

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Rhumbline Advisers - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

IFP Advisors Inc Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

(VERV) Technical Data - Stock Traders Daily

Mar 06, 2025
pulisher
Mar 05, 2025

Verve Therapeutics (NASDAQ:VERV) Shares Gap Down After Analyst Downgrade - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Verve Therapeutics (NASDAQ:VERV) Price Target Cut to $15.00 by Analysts at Royal Bank of Canada - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Verve Therapeutics price target lowered to $15 from $17 at RBC Capital - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 04, 2025
pulisher
Mar 03, 2025

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

How Verve Therapeutics Is Attracting Talent: New Equity Compensation Package Details - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Analysts Set Expectations for VERV Q1 Earnings - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire

Mar 02, 2025
pulisher
Mar 02, 2025

HC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) Stock - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire

Mar 01, 2025
pulisher
Mar 01, 2025

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 01, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts VERVE Therapeutics price target to $15 By Investing.com - Investing.com Canada

Feb 28, 2025
pulisher
Feb 28, 2025

Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Verve Can Shrug Off Vertex Loss But Lilly Opt-In Is Crucial - News & Insights

Feb 28, 2025
pulisher
Feb 28, 2025

Verve TherapeuticsKey Data Catalysts, Major Share Price Volatility In Play In Q2 - Seeking Alpha

Feb 28, 2025
pulisher
Feb 28, 2025

Buy Rating for Verve Therapeutics: Promising Program Progress and Strong Financial Position - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Verve Therapeutics: Buy Rating Backed by Promising VERVE-102 Program and Strategic Catalysts - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

Verve Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance UK

Feb 28, 2025
pulisher
Feb 27, 2025

Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Verve Therapeutics: Q4 Earnings Snapshot - Houston Chronicle

Feb 27, 2025
pulisher
Feb 27, 2025

Verve Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Verve Therapeutics reports Q4 EPS (58c), consensus (67c) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Vertex ends gene editing research pact with Verve - BioPharma Dive

Feb 27, 2025
pulisher
Feb 27, 2025

Verve Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Verve Therapeutics: Q4 Earnings Snapshot -February 27, 2025 at 07:33 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Can Verve's Gene Editing Trials Deliver? Key PCSK9 Data Coming in 2025 With $524M War Chest - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

VERV STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 24, 2025

Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire

Feb 24, 2025
pulisher
Feb 24, 2025

VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Feb 24, 2025
pulisher
Feb 23, 2025

Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineVERV - ACCESS Newswire

Feb 23, 2025

Verve Therapeutics Inc Azioni (VERV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Capitalizzazione:     |  Volume (24 ore):